SIGLEC10抗体

+ +

•  

   

     Gel: 8%SDS-PAGE, Lysate: 40 μg, Lane 1-2: Hela and SKOV3 cell lysates, Primary antibody: P05282(SIGLEC10 Antibody) at dilution 1/650, Secondary antibody: Goat anti rabbit IgG at 1/5000 dilution, Exposure time: 1 minute    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human tonsil tissue using P05282(SIGLEC10 Antibody) at dilution 1/50. (Original magnification: ×200)    

  
  

SIGLEC10 (Sialic acid-binding immunoglobulin-type lectin 10) is a transmembrane protein belonging to the Siglec family of immune regulatory receptors, primarily expressed on subsets of immune cells such as macrophages, dendritic cells, and B cells. It recognizes sialic acid-containing glycans on cell surfaces, transmitting inhibitory signals through immunoreceptor tyrosine-based inhibitory motifs (ITIMs) in its cytoplasmic domain. These signals modulate immune responses, maintaining tolerance and preventing excessive inflammation. Dysregulation of SIGLEC10 has been linked to autoimmune diseases, cancer immune evasion, and chronic inflammatory conditions.

SIGLEC10 antibodies are tools or therapeutic agents designed to target this receptor. Agonistic antibodies can enhance SIGLEC10’s immunosuppressive activity, potentially treating autoimmune disorders. Conversely, antagonistic antibodies block SIGLEC10 signaling, aiming to counteract immune suppression in cancers or chronic infections. Recent studies highlight SIGLEC10’s interaction with CD24 as a "don’t eat me" signal, protecting cancer cells from phagocytosis. Antibodies disrupting this axis are being explored to boost anti-tumor immunity.

Research on SIGLEC10 antibodies remains in early stages, with ongoing efforts to clarify their mechanistic roles and optimize specificity. Their dual potential in either suppressing or activating immune responses makes them promising yet complex candidates for immunotherapy.